ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 991

Familial Aggregation of Rheumatoid Arthritis in Sarcoidosis: A Register-Based Case-Control Study in Sweden

Elizabeth V. Arkema, Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: family studies, registries, rheumatoid arthritis (RA) and sarcoidosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Epidemiology and Public Health I: Inflammatory Arthritis – Risk and Impact

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Sarcoidosis is an inflammatory disease with unknown etiology that primarily affects the lungs and lymph glands. Sarcoidosis shares some features with rheumatoid arthritis (RA), such as joint involvement and genetic susceptibility related to HLA class II alleles. The aim of this study was to estimate the familial co-aggregation of sarcoidosis with RA.

Methods:  A case-control study using Swedish national registers was performed. Adults with sarcoidosis (cases) were identified from the National Patient Register (NPR) and required to have at least two visits listing a sarcoidosis ICD code 2001-2013. Population controls matched 10:1 on age, sex and county who were living in Sweden with no history of sarcoidosis at the time the case was diagnosed (index date) were identified from the Total Population Register. The Multigeneration Register was used to identify parents, siblings and children. Family members with at least two visits listing an ICD code for RA were identified from the NPR (2001-2013). A subset was identified who had any listing of seropositive RA (M05, M08.0). Mean number of first degree relatives (FDR) was calculated for cases and controls to assure that family structures did not differ by case status. Familial relative risks for sarcoidosis associated with having a family history of RA were estimated using odds ratios and 95% confidence intervals (OR 95%CI) from conditional logistic regression models. Models were stratified by sex of the proband. In a sensitivity analysis, cases and controls with comorbid RA were excluded.

Results: 11,669 sarcoidosis cases and 115,581 controls were identified. The average age at diagnosis was 50 and 55% were male. Cases and controls had a similar mean number of FDRs (4.8 and 4.7, respectively). A higher proportion of cases had a family history of RA compared to controls (4.4% vs. 3.3%). The OR for sarcoidosis comparing any family history of RA to no family history was 1.4 (95%CI 1.2, 1.5). The OR associated with a family history of seropositive RA was similar (OR 1.3; 95%CI 1.1, 1.6). The OR was higher for male probands (OR 1.5; 95%CI 1.3, 1.7) compared to females (OR 1.2; 95%CI 1.0, 1.4). When excluding cases and controls with comorbid RA (2% and 1%, respectively), the OR was 1.3 (95%CI 1.2, 1.5).

Conclusion:  There exists a 40% increased risk for sarcoidosis associated with a family history of RA. This indicates that, to some extent, the two diseases share a common etiology and an overlap in genetic risk.


Disclosure: E. V. Arkema, None;

To cite this abstract in AMA style:

Arkema EV. Familial Aggregation of Rheumatoid Arthritis in Sarcoidosis: A Register-Based Case-Control Study in Sweden [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/familial-aggregation-of-rheumatoid-arthritis-in-sarcoidosis-a-register-based-case-control-study-in-sweden/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/familial-aggregation-of-rheumatoid-arthritis-in-sarcoidosis-a-register-based-case-control-study-in-sweden/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology